(Reuters) – Altimmune said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease.
The drug, pemvidutide, showed a subsiding of metabolic dysfunction-associated steatohepatitis (MASH), or non-alcoholic steatohepatitis (NASH), without a worsening of liver scarring in up to 59.1% of participants in the 212-patient trial.
A weight loss of up to 6.2% was also seen in the trial.
Despite the positive results, shares were down 56% premarket.
Pemvidutide is being studied separately as an obesity treatment.
(Reporting by Puyaan Singh in Bengaluru; Editing by Devika Syamnath and Sriraj Kalluvila)
